SEMA3A can also be produced by cancer cells23 and recent evidence indicates that NRP1, like PD-1, is upregulated on dysfunctional tumor-specific CD8+ T cells and can modulate their anti-tumor response19,24–26. This evidence concerns the gene CD8A and neoplasm.